84/100BBoston Scientific stock forecast 2026–2030What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for Boston Scientific is 54.65, 23.2% above the current price of 44.35. Their targets range from 46.00 to 71.00.
Of the 25 firms that rated Boston Scientific in the past 12 months, 18 rate it buy or strong buy, 7 hold and 0 sell or strong sell (each firm at its latest rating): a Buy consensus.
Analysts' 1-year price targets range from 46.00 to 71.00, with an average of 54.65.
| Buy | 18 | |
| Hold | 7 | |
| Sell | 0 |
12-month price target
| Highest target | 71.00 |
| Average target | 54.65 |
| Lowest target | 46.00 |
| Current price | 44.35 |
Boston Scientific price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their Boston Scientific price target and rating?
How analysts rate Boston Scientific, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
18 of 25 firms rate it buy now, against 17 of 17 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Boston Scientific analyst upgrades, downgrades and price targets
The latest rating change came on 30 October 2026, when TD Cowen downgraded Boston Scientific from Buy to Hold. The most recent new target came from RBC Capital on 29 October 2026: 52.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 30 Oct 2026 | TD Cowen | Downgraded · Buy → Hold | — | — | — |
| 29 Oct 2026 | RBC Capital | Reiterated · Outperform | 70.00 → 52.00 | -25.7% | 42.29 |
| 29 Oct 2026 | Deutsche Bank | — | 60.00 → 48.00 | -20.0% | 42.27 |
| 29 Oct 2026 | BTIG | Reiterated · Buy | 56.00 → 49.00 | -12.5% | 42.43 |
| 29 Oct 2026 | Leerink Partners Mike Kratky | Reiterated · Outperform | 60.00 → 50.00 | -16.7% | 42.43 |
| 29 Oct 2026 | Mizuho Securities Anthony Petrone | — | 55.00 → 50.00 | -9.1% | 42.43 |
| 29 Oct 2026 | Canaccord Genuity William Plovanic | Reiterated · Buy | 66.00 → 48.00 | -27.3% | 42.43 |
| 29 Oct 2026 | Jefferies | Downgraded · Buy → Hold | — | — | — |
| 28 Oct 2026 | Jefferies | — | 100.00 → 46.00 | -54.0% | 42.43 |
| 28 Oct 2026 | Needham | Reiterated · Buy | 57.00 → 48.00 | -15.8% | 43.03 |
| 26 Oct 2026 | Stifel Nicolaus | Reiterated · Buy | 60.00 → 55.00 | -8.3% | 45.69 |
| 14 Oct 2026 | Truist Financial | Reiterated · Buy | 62.00 → 51.00 | -17.7% | 42.85 |
| 13 Oct 2026 | Mizuho Securities | — | 70.00 → 55.00 | -21.4% | 43.84 |
| 6 Oct 2026 | Barclays | — | 89.00 → 48.00 | -46.1% | 42.19 |
| 3 Oct 2026 | Bernstein Lee Hambright | — | 112.00 → 54.00 | -51.8% | 42.60 |
| 23 Sept 2026 | Wells Fargo Larry Biegelsen | — | 50.00 → 48.00 | -4.0% | 44.62 |
| 21 Sept 2026 | Oppenheimer Suraj Kalia | Reiterated · Outperform | 85.00 → 65.00 | -23.5% | 43.34 |
| 17 Sept 2026 | Citigroup | Downgraded · Buy → Neutral | — | — | — |
| 9 Sept 2026 | BTIG Marie Thibault | Reiterated · Buy | 60.00 → 56.00 | -6.7% | 44.98 |
| 31 Jul 2026 | Argus Research | Downgraded · Buy → Hold | — | — | — |
| 30 Jul 2026 | RBC Capital Shagun Singh | Reiterated · Outperform | 85.00 → 70.00 | -17.6% | 44.80 |
| 30 Jul 2026 | UBS | Reiterated · Buy | 74.00 → 67.00 | -9.5% | 44.90 |
| 30 Jul 2026 | Deutsche Bank Pito Chickering | — | 60.00 | — | 44.93 |
| 30 Jul 2026 | Robert W. Baird | — | 70.00 → 56.00 | -20.0% | 46.04 |
| 30 Jul 2026 | Canaccord Genuity | Reiterated · Buy | 70.00 → 66.00 | -5.7% | 46.04 |
| 30 Jul 2026 | Wells Fargo | Reiterated · Equal Weight | 55.00 → 50.00 | -9.1% | 46.04 |
| 30 Jul 2026 | Leerink Partners | — | 74.00 → 60.00 | -18.9% | 46.04 |
| 30 Jul 2026 | Raymond James Jayson Bedford | — | 57.00 | — | 46.04 |
| 29 Jul 2026 | BTIG Marie Thibault | Reiterated · Buy | 65.00 → 60.00 | -7.7% | 46.04 |
| 29 Jul 2026 | Stifel Nicolaus Rick Wise | — | 65.00 → 60.00 | -7.7% | 46.55 |
| 28 Jul 2026 | UBS | — | 120.00 → 74.00 | -38.3% | 45.51 |
| 27 Jul 2026 | Oppenheimer | Reiterated · Outperform | 90.00 → 85.00 | -5.6% | 45.88 |
| 16 Jul 2026 | Truist Financial | Reiterated · Buy | 64.00 → 62.00 | -3.1% | 44.60 |
| 15 Jul 2026 | Mizuho Securities Anthony Petrone | Reiterated · Outperform | 90.00 → 70.00 | -22.2% | 42.63 |
| 13 Jul 2026 | RBC Capital Shagun Singh | Reiterated · Outperform | 100.00 → 85.00 | -15.0% | 44.72 |
| 8 Jul 2026 | Needham Mike Matson | Reiterated · Buy | 77.00 → 57.00 | -26.0% | 45.30 |
| 6 Jul 2026 | Evercore ISI | Reiterated · Outperform | 96.00 → 65.00 | -32.3% | 44.55 |
| 25 Jun 2026 | Stifel Nicolaus | Reiterated · Buy | 75.00 → 65.00 | -13.3% | 44.46 |
| 12 Jun 2026 | Piper Sandler | — | 65.00 | — | 47.17 |
| 4 Jun 2026 | Truist Financial | Reiterated · Buy | 85.00 → 64.00 | -24.7% | 49.35 |
| 2 Jun 2026 | BTIG Marie Thibault | — | 110.00 → 65.00 | -40.9% | 47.68 |
| 1 Jun 2026 | Canaccord Genuity | Reiterated · Buy | 71.00 → 70.00 | -1.4% | 48.31 |
| 29 May 2026 | Wolfe Research | Downgraded · Outperform → Peer Perform | — | — | — |
| 28 May 2026 | Goldman Sachs | — | 84.00 → 71.00 | -15.5% | 50.46 |
| 28 May 2026 | Robert W. Baird | — | 75.00 → 70.00 | -6.7% | 50.46 |
| 28 May 2026 | Leerink Partners Mike Kratky | Reiterated · Outperform | 118.00 → 74.00 | -37.3% | 50.46 |
| 28 May 2026 | Barclays | Reiterated · Overweight | 96.00 → 89.00 | -7.3% | 50.46 |
| 28 May 2026 | Wells Fargo Larry Biegelsen | Downgraded · Overweight → Equal Weight | 75.00 → 55.00 | -26.7% | 50.46 |
| 27 May 2026 | Stifel Nicolaus Rick Wise | — | 85.00 → 75.00 | -11.8% | 51.07 |
| 19 May 2026 | Robert W. Baird | — | 78.00 → 75.00 | -3.8% | 55.92 |
Boston Scientific EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Analysts expect Boston Scientific's EPS to grow 20.0% a year until 2028.
Analysts expect Boston Scientific's revenue to grow 2.9% a year until 2028, slower than over the last 5 years (15.2% a year) and the last 3 years (16.5%).
Revenue
EPS
Does Boston Scientific beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 5.3% off the result, either way, and their revenue estimate 2.4%, over the last 12 quarters.
- EPS beats
- 83 / 136
- Revenue beats
- 75 / 120
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +5.3%
- Since
- February 1993
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 28 Oct 2026 | 0.73 | 0.73 | +0.4% | 5.09B | 5.14B | +1.0% |
| Q2 FY2026 | 29 Jul 2026 | 0.84 | 0.86 | +3.0% | 5.38B | 5.44B | +1.2% |
| Q1 FY2026 | 22 Apr 2026 | 0.79 | 0.80 | +1.5% | 5.17B | 5.20B | +0.6% |
| Q4 FY2025 | 4 Feb 2026 | 0.78 | 0.80 | +2.4% | 5.28B | 5.29B | +0.1% |
| Q3 FY2025 | 22 Oct 2025 | 0.71 | 0.75 | +5.0% | 4.97B | 5.07B | +1.9% |
| Q2 FY2025 | 23 Jul 2025 | 0.73 | 0.75 | +3.4% | 4.89B | 5.06B | +3.4% |
| Q1 FY2025 | 23 Apr 2025 | 0.67 | 0.75 | +11.4% | 4.57B | 4.66B | +2.0% |
| Q4 FY2024 | 5 Feb 2025 | 0.66 | 0.70 | +6.5% | 4.42B | 4.56B | +3.2% |
| Q3 FY2024 | 23 Oct 2024 | 0.59 | 0.63 | +7.1% | 4.04B | 4.21B | +4.2% |
| Q2 FY2024 | 24 Jul 2024 | 0.58 | 0.62 | +6.3% | 4.03B | 4.12B | +2.3% |
| Q1 FY2024 | 24 Apr 2024 | 0.51 | 0.56 | +8.9% | 3.68B | 3.86B | +4.7% |
| Q4 FY2023 | 31 Jan 2024 | 0.51 | 0.55 | +7.8% | 3.59B | 3.73B | +3.7% |
Boston Scientific stock price 2026–2030: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
If Boston Scientific's earnings keep growing at the 3.2% a year analysts expect to FY2028, it would earn about 3.57 a share in FY2030. At the P/E it has traded at over the last five years (18.7 to 53.5) that is 66.89 to 191.25 a share, or 144.01 at its average P/E of 40.3. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 3.16 | 59.19 | 127.42 | 169.22 |
| FY2027 | 3.12 | 58.42 | 125.78 | 167.04 |
| FY2028 | 3.35 | 62.78 | 135.16 | 179.49 |
| FY2029 (extrapolated) | 3.46 | 64.80 | 139.51 | 185.28 |
| FY2030 (extrapolated) | 3.57 | 66.89 | 144.01 | 191.25 |
Each year's EPS is the analysts' consensus to FY2028; the years after grow 3.2% a year (the analysts' growth, at most 15%). Bear, base and bull apply the lowest, average and highest P/E of today and the last five fiscal year ends, leaving out any above 60, the mark of a year of collapsed earnings (18.7, 40.3, 53.5).
Is Boston Scientific stock undervalued or overvalued?How does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
Boston Scientific's P/E of 18.7 is near the bottom of its 5-year range (18.0 to 117.7, median 74.9). It is within 5% of its 5-year low. Analysts expect slower growth than in recent years, so the low P/E may be deserved. Growing 20.0% a year, Boston Scientific earns a P/E of 20.0 at a PEG of 1 (at most 25): × the next twelve months' EPS of 3.13, a fair value of 62.64; the price, 44.35, is 29.2% below it. Its forward P/E, on the consensus for FY2026, is 14.0.
Fair value on growth is a P/E equal to the EPS growth analysts expect a year (a PEG of 1, at most 25) times the earnings per share of the next twelve months; the ends of the bar are a PEG of 0.75 and 1.25 (a P/E of 15.0 and 25.0). The price against its P/E range
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 18.71
- Five-year median P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 74.88
- Five-year P/E range
- 18.0 – 117.7
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 14.02
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 5.80
- To the average targetWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
- +23.2%
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 235.690 | 464.49205Price 235.69627 | +97.1% | |
| 28.860 | 56.2634Price 28.8696 | +94.9% | |
| 199.110 | 384.58163Price 199.112,644 | +93.1% | |
| 123.990 | 237.24178Price 123.99297 | +91.3% | |
| 157.820 | 297.58169Price 157.82471 | +88.6% | |
| 162.670 | 305.52160Price 162.67396 | +87.8% | |
| 216.610 | 405.38304Price 216.61507 | +87.1% |
Furthest below the fair value on each stock's page, updated every day.